Research programme: tapentadol - Ensysce Biosciences

Drug Profile

Research programme: tapentadol - Ensysce Biosciences

Alternative Names: PF 16; Tapentadol Bio-MD™ System

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 24 Feb 2016 Discontinued for Pain in USA (PO)
  • 19 Jan 2016 Signature Therapeutics merged into Ensysce Biosciences
  • 03 Sep 2012 Research programme: tapentadol - Signature Therapeutics is available for licensing as of 03 Sep 2012. www.ensysce.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top